News & Insights

Nanopharm Limited and Sciarra Laboratories Inc. announce Strategic Alliance

Nanopharm Limited “Nanopharm” (Newport, UK) and Sciarra Laboratories (Hicksville and Carmel – New York, US) “Sciarra” today announced that they had entered into a Strategic Alliance to provide the world’s leading fully integrated CDMO services for the development and GMP manufacture of pressurized metered dose inhalers (MDIs).

The agreement provides Nanopharm the opportunity to combine its SmartTrack™ development services with access to MDI drug product manufacturing capabilities at GMP at Sciarra. The combination of this pairing enables the establishment of broader expertise and know-how related to analytical methods and manufacturing methods related to the research, development and commercialization of MDIs. Both companies realise the potential for this collaboration, most importantly in providing their growing client list with a comprehensive, science-led and manufacturing excellence-based service.

As part of this alliance, Nanopharm will support Sciarra with respect to project management and access to its SmartTrack™ platform. Sciarra will continue to provide their expert-led formulation and manufacturing services, with input from the wider group. Collectively the new offering will be based in over 30,000 square feet of state-of-the-art R&D and GMP manufacturing facilities in the UK and US with over 50 dedicated and experienced personnel that can address all aspects of the value chain including devices. This combination offers for the first time a truly “one stop” shop for clients committed to the development and manufacture of MDI drug products.

Nanopharm has experienced significant growth over the last 2 years and this expansion of capability is a further commitment to a client base that sees it as the “go to” group in the space of OINDP research and development.

Commenting on the announcement Jag Shur CEO of Nanopharm said: “Our strategic alliance with Sciarra marks a significant milestone for Nanopharm, as we now focus on translating our SmartTrack™ development platform to enable manufacture of MDIs from early phase development through to commercial manufacture.

 Adding further comment on this announcement, Robert Price, Founder & CSO of Nanopharm said: “Our collaboration with Sciarra will enable us to provide science-led development and manufacture of MDIs, which will ultimately allow us to help our clients by de-risking their program and moving it swiftly into the pivotal phases of the drug product development value-chain.

Christopher Sciarra CEO of Sciarra commented: “We are excited at the prospect of working with Nanopharm in this key area and we are now well placed to drive the considerable value that exists for our clients. The combination of the state of art analytical and manufacturing capabilities for MDIs, will help us to accelerate the development programs for our clients”.

Contact:

To learn more about what Nanopharm-Sciarra can offer your program please contact Aimee Anderson. E-mail: a.anderson@nanopharm.co.uk, Tel: +44 (0)1633504776